Therapy Areas: Cardiovascular
Cipher Pharmaceuticals introduces Brinavess in Canada
26 October 2018 -

Cipher Pharmaceuticals, a specialty pharmaceutical company, has launched its Brinavess (vernakalant hydrochloride) in Canada, it was reported yesterday.

The product is intended for the rapid conversion of recent onset atrial fibrillation to sinus rhythm for non-surgery patients with duration of atrial fibrillation less than seven days, and post-cardiac surgery patients with duration of atrial fibrillation less than three days. It is an antiarrhythmic drug that acts preferentially in the atria by prolonging atrial refractoriness and slowing impulse conduction in a rate-dependent fashion.

St Michael's Hospital staff cardiac electrophysiologist and University of Toronto cardiology division department director Dr Paul Dorian, said, 'Brinavess offers an important safe and effective option for the treatment of recent onset atrial fibrillation. In Phase III trials, Brinavess demonstrated a median time to cardioversion of 11 minutes in 51% of the treated AF patients and 97% of these treated patients maintained sinus rhythm at 24 hours post treatment.'

Login
Username:

Password: